Latest Hematopoietic stem cell Stories
HOUSTON -- Components of the blood or hematopoietic system derive from stem cell subtypes rather than one single stem cell that gives rise to all the different kinds of blood cells equally, said scientists from Baylor College of Medicine (www.bcm.edu) in a report that appears in the current issue of the journal Cell Stem Cell (www.cell.com/cell-stem-cell/) "While previous reports in journals have hinted at the possibility of stem cell subtypes, this study represents the clearest data to...
Biologists at UC San Diego have identified the specific region in vertebrates where adult blood stem cells arise during embryonic development.Their discovery, which appears in a paper in this week's early online edition of the journal Nature, is a critical first step for the development of safer and more effective stem cell therapies for patients with leukemia, multiple myeloma, anemia and a host of other diseases of the blood or bone marrow.The researchers say their time-lapse imaging of the...
HONG KONG, Feb. 11 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation ("CCBC" or "the Company") (NYSE: CO), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Securities and Exchange Commission ("SEC") declared the Company's registration statement effective on February 9, 2010. The registration statement relates to the ordinary shares underlying warrants and certain...
New research in the FASEB Journal shows that bone marrow cells fuse to different types of cells, including embryonic stem cells, creating new hybrids that may evade immune rejectionUsing cells from mice, scientists from Iowa and Iran have discovered a new strategy for making embryonic stem cell transplants less likely to be rejected by a recipient's immune system. This strategy, described in a new research report appearing in the February 2010 print issue of The FASEB Journal...
WASHINGTON "“ Bone marrow is a leading source of adult stem cells, which are increasingly used for research and therapeutic interventions, but extracting the cells is an arduous and often painful process. Now, researchers have found evidence that fat tissue, known as adipose tissue, may be a promising new source of valuable and easy-to-obtain regenerative cells called hematopoietic stem and progenitor cells (HSPCs), according to a study prepublished online in Blood, the official journal of...
WASHINGTON, Jan. 27 /PRNewswire-USNewswire/ -- Bone marrow is a leading source of adult stem cells, which are increasingly used for research and therapeutic interventions, but extracting the cells is an arduous and often painful process. Now, researchers have found evidence that fat tissue, known as adipose tissue, may be a promising new source of valuable and easy-to-obtain regenerative cells called hematopoietic stem and progenitor cells (HSPCs), according to a study prepublished online...
Scientists at Fred Hutchinson Cancer Research Center have cleared a major technical hurdle to making umbilical-cord-blood transplants a more widely-used method for treating leukemia and other blood cancers.In a study published in the Jan.17 edition of Nature Medicine, Colleen Delaney, M.D., and colleagues describe the first use of a method to vastly expand the number of stem/progenitor cells from a unit of cord blood in the laboratory that were then infused into patients resulting in...
NEW YORK, Dec. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Mesenchymal Stem Cells, Advances & Applications http://www.reportlinker.com/p0167257/Mesenchymal-Stem-Cells-Advances--Applications.html Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, and potentially, neuronal...
TAIPEI, Taiwan, Dec. 7 /PRNewswire-Asia/ -- TaiGen Biotechnology Co., Ltd. announced today the presentation of Phase I and preclinical data for TG-0054, the Company's chemokine receptor CXCR4 antagonist and a novel, potent stem cell mobilizer, at the ASH Annual Meeting held in New Orleans, the US, from December 5 to 8, 2009. The clinical data of Phase 1 study will be presented. In this randomized, double-blind, placebo-controlled, sequential ascending single intravenous dose study,...
LA JOLLA, Calif., Nov. 16 /PRNewswire/ -- Fate Therapeutics, Inc. announced today that it has completed a $30 million Series B financing led by OVP Venture Partners. Joining OVP Venture Partners in the financing is a syndicate of corporate investors, including Astellas Venture Management, Genzyme Ventures and a third undisclosed corporate investor. The three co-leaders of the Company's Series A financing, ARCH Venture Partners, Polaris Venture Partners and Venrock, also participated in...
